Jacob Kimmel

Jacob Kimmel is a co-founder and Head of Research at NewLimit, where efforts focus on developing epigenetic reprogramming medicines since March 2022. Previously, Kimmel served as a Principal Investigator at Calico Life Sciences, leading a computational and experimental biology laboratory tackling aging and age-related diseases from May 2018 to March 2022. Working at Calico, Kimmel also contributed as a Computational Fellow and Data Scientist, utilizing a blend of computational and experimental techniques. Academic credentials include a Ph.D. in Developmental & Stem Cell Biology from the University of California, San Francisco, where Kimmel conducted research on stem cell decision-making. A brief internship at IBM allowed for the application of deep learning methods in cell engineering.